奥尔金-A,一个TPX2-奥罗拉A小分子抑制剂破坏了阿利塞尔提布诱导的多重合体性在攻击性扩散大B细胞淋巴瘤中
Patrick J Conway1, Bárbara De La Peña Avalos2, Jonathan Dao3
1Department of Molecular Immunology & Microbiology, University of Texas Health Science Center San Antonio, 7703 Floyd Curl Drive, San Antonio, Texas, USA; Department of Biomedical Sciences, Keiser University, 2600 N Military Trl, West Palm Beach, Florida, USA.
概括
一种癌症药物阿利塞尔蒂布 (Alisertib) 可以导致多体性,一种药物耐药性的形式. 将其与Aurkin A结合起来会破坏这种多体化,增加扩散型大B细胞淋巴瘤中的癌细胞死亡.
科学领域:
- 在瘤学瘤学.
- 细胞生物学 细胞生物学
- 药理学 药理学是指药理学的学科.
背景情况:
- 化疗可以诱导多聚合体性,一种遗传药物耐药性的机制,导致侵袭性癌症.
- 阿利塞尔蒂布是一种光激酶A (AK-A) 抑制剂,在扩散型大B细胞淋巴瘤 (DLBCL) 中引起细胞循环中断和多氨基化.
研究的目的:
- 调查DLBCL中阿利塞尔提布诱导的多体化机制.
- 评估结合阿利谢蒂布与AK-A/TPX2抑制剂Aurkin A的疗效,以克服多化和增强亡.
主要方法:
- 在U2932和VAL细胞系中使用化流细胞计量来量化alisertib诱导的多重性质.
- 生成稳定的FUCCI U2932细胞系,用于监测细胞周期进展 (S/G2/M的双子三叶草,G1的cdt1-mKO).
- 在实验室和体内使用VAL小鼠异种移植模型评估多化和亡.
主要成果:
- 5天后,alisertib (1μM) 在48%的U2932细胞中诱导了8n+多质合体.
- 与Aurkin A和alizertib的联合治疗依赖于剂量,破坏了由alizertib诱导的多化和增加的亡.
- 发现阿利塞尔蒂布通过内分泌酶诱导多体,这一过程被奥尔金A治疗逆转.
- 在体内研究表明,在VAL小鼠异种移植模型中,Aurkin A加上alisertib显著降低了多体积.
结论:
- 阿利塞尔蒂布通过内分细胞形成诱导DLBCL中的多聚体性,从而导致药物耐药性.
- 阿尔金A与阿利塞尔蒂布协同作用,降低所需的阿利塞尔蒂布剂量以破坏多体积并增加亡.
- 与Aurkin A和alisertib的联合治疗提供了一个有希望的策略,以克服DLBCL中的化学抵抗.
相关概念视频
Abnormal Proliferation
4.5K
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.5K
Inhibition of Cdk Activity
4.7K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.7K
The Intrinsic Apoptotic Pathway
6.5K
Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...
6.5K
Targeted Cancer Therapies
7.5K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.5K


